Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
Blood (2019) 134 (Supplement_1): 14.
Currently there are no citedby results. Try again later.
